Related coverage linked through entity extraction aliases.
May 23, 2026
Greenwich LifeSciences received a second Nasdaq notice for late filing of its Form 10-Q, following a prior notice for a late Form 10-K. The company's stock continues trading on the Nasdaq Capital Market while it works to file the overdue reports.
May 20, 2026
Compugen said it will release fourth quarter and full year 2025 results on March 2, 2026, and present at the Needham Virtual Healthcare Conference on April 13. The company also outlined its Phase 1 and Phase 3 immuno-oncology pipeline programs.
May 13, 2026
Immunic reported first-quarter 2026 results and said a $200 million upfront private placement is expected to fund phase 3 ENSURE trials in relapsing MS. The financing could provide up to $400 million in gross proceeds.
May 07, 2026
argenx reported $1.3B in Q1 2026 global product net sales (63% YoY growth). The FDA PDUFA target date for seronegative gMG is May 10, 2026. Positive ADAPT OCULUS results support an oMG label expansion. Pipeline milestones include myositis readout in Q3 2026 and MMN readout in Q4 2026.
May 02, 2026
Dianthus, Taysha and aTyr disclosed inducement equity grants for newly hired employees under Nasdaq Listing Rule 5635(c)(4), detailing share awards, vesting schedules and exercise prices.
Apr 07, 2026
Silo Pharma said the Japan Patent Office issued a Notice of Allowance for a patent application covering SPC-15, its intranasal PTSD therapeutic. The allowed application covers composition and method claims, with formal patent grant expected to follow.
Mar 24, 2026
Elicio Therapeutics granted inducement stock options to new employees, with one grant of 1,600 options at $12.16 per share and another of 30,300 options at $8.59 per share. The clinical-stage biotech company is developing novel immunotherapies targeting mKRAS-positive cancers, with its ELI-002 program showing promising Phase 1 results including 16.3-month median recurrence-free survival.
Feb 27, 2026
Gilead Sciences has agreed to buy immunotherapy cancer biotech Arcellx in a deal worth $7.8 billion, deepening its bet on cancer immunotherapy and its existing partnership with the company.
Feb 23, 2026
Trinity Biotech plc received two separate non-compliance notices from Nasdaq in February 2026 for failing to meet minimum bid price and market value requirements, with 180-day periods to regain compliance or face potential delisting.
Feb 25, 2026
Medtronic's diabetes unit MiniMed is seeking up to $7.86 billion valuation in its U.S. IPO while cutting 81 jobs at its Northridge facility ahead of the planned separation into a standalone publicly traded company.
Feb 20, 2026
Vir Biotechnology is set to report Q4 2025 earnings on Feb 23, 2026, with analysts expecting revenue of $19.91-$23.18 million and a loss of $0.41-$0.50 per share, marking a 61% year-over-year revenue increase.
Feb 17, 2026
Compass Pathways reported positive phase 3 results for COMP360 psilocybin in treatment-resistant depression, showing statistically significant symptom reduction. The company plans to discuss FDA filing with a New Drug Application expected in Q4 2026.
Feb 17, 2026
The provided source articles lack sufficient accessible factual content for synthesis. One article is inaccessible, another covers unrelated stock performance topics, and the third concerns a different company entirely.
Feb 16, 2026
Compass Pathways' COMP360 synthetic psilocybin met primary endpoints in Phase 3 trials for treatment-resistant depression, with the company planning to submit a new drug application in Q4 2026.
Feb 14, 2026
Disc Medicine received a complete response letter from the FDA for bitopertin as a treatment for erythropoietic protoporphyria. The FDA acknowledged the drug lowers PPIX levels but requires evidence from the ongoing Phase 3 APOLLO study before approval.
Feb 13, 2026
Aethlon Medical reported Q3 2026 financial results with a $2.06 million operating loss while advancing its Australian oncology trial of the Hemopurifier device. The company achieved 27% year-to-date cost reductions and targets a late March safety review.
